Related Experiment Video

Updated: Feb 14, 2026

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

21.2K

Pediatric epilepsy: Five new things

Kelly Knupp1, Susan Koh1, Kristen Park1

  • 1University of Colorado Denver and Children's Hospital Colorado, Aurora.

Neurology. Clinical Practice
|February 15, 2018
PubMed

Insights

Pediatric epilepsy research is advancing with new animal models and genetic discoveries. Progress in drug therapy and understanding comorbidities improves treatment outcomes for children with epilepsy.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Translational Research

Background:

  • Pediatric epilepsy presents unique seizure types and syndromes distinct from adult epilepsy.
  • Current treatment goals include seizure freedom, minimal side effects, and normal function, which are not always achieved.
  • Significant advancements are enhancing the understanding and management of childhood epilepsy.

Purpose of the Study:

  • To review key areas of progress in pediatric epilepsy research and treatment.
  • To highlight advancements aimed at achieving seizure freedom and improving quality of life for children with epilepsy.

Main Methods:

  • Development of specific research animal models tailored to pediatric epilepsy features.
  • Identification and genetic characterization of pediatric epilepsy syndromes.
  • Analysis of comparative drug trials and research on epilepsy comorbidities.

Main Results:

  • Novel animal models are being created to better represent distinct pediatric epilepsy types.
  • Improved genetic identification is leading to more targeted and effective treatments for some children.
  • Three new medications have been approved for pediatric use, expanding therapeutic options.

Conclusions:

  • Advances in research models, genetic understanding, and pharmacotherapy are improving pediatric epilepsy care.
  • Comparative drug trials and awareness of comorbidities enable more informed treatment choices.
  • Continued progress offers hope for achieving better outcomes and improved quality of life for children with epilepsy.

More Related Videos

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

1.7K
Robotic-Guided Stereoelectroencephalography for Invasive Epilepsy Monitoring11:28

Robotic-Guided Stereoelectroencephalography for Invasive Epilepsy Monitoring

Published on: June 13, 2025

1.4K

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
279
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
251
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
316